HBV Host Factors CREBH SCARF2 NTCP Entry Mechanism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis B virus (HBV) infection lack targeted drugs for cure, with existing therapies like alpha-interferon and nucleic acid analogs being ineffective due to the stable presence of covalently closed circular DNA (cccDNA) in host cells, which acts as a transcriptional template for viral genes and is difficult to eradicate.
Innovation Solution
Identification of specific host factors such as CREBH and SCARF2 proteins, which facilitate HBV entry and transcription by interacting with the virus, allowing for enhanced infection efficiency and potential therapeutic targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If PEG is added to enhance HBV infection efficiency in vitro, then infection efficiency is improved, but the requirement for high viral titer remains and the mechanism is incomplete without specific host factors
Solution Approach 1:
The patent identifies NTCP as a specific host factor that acts as an intermediary between HBV and hepatocytes. NTCP serves as the entry receptor that mediates viral attachment and internalization, completing the infection mechanism that PEG alone cannot achieve. This resolves the contradiction by providing a specific molecular mediator that enhances infection efficiency without requiring high viral titers or artificial PEG supplementation.
Solution Approach 2:
The patent changes the key parameter from artificial PEG-mediated enhancement to natural NTCP receptor-mediated entry. By identifying and utilizing the specific host factor NTCP, the infection system transitions from an artificial, inefficient process requiring high viral titers and PEG to a physiological, efficient process that occurs at natural viral concentrations.
2Productivity
If high viral titer is used to achieve high-efficiency infection in vitro, then infection efficiency is improved, but the conditions differ significantly from in vivo infection
Solution Approach 1:
NTCP serves as the physiological intermediary that enables HBV to infect hepatocytes under conditions that mirror in vivo infection. The presence of NTCP allows the virus to enter cells at natural viral concentrations, making the in vitro system adaptable and relevant to physiological conditions without requiring artificial high-titer supplementation.
3Stability of the object's composition
If cccDNA is present in host cells as a stable transcriptional template, then viral gene expression is maintained, but targeted drugs cannot eradicate the infection
Solution Approach 1:
The patent applies preliminary action by blocking HBV entry at the NTCP receptor level before cccDNA formation occurs. By preventing viral internalization and nuclear transport through NTCP inhibition, the virus cannot establish the stable cccDNA reservoir in the first place, thereby preventing the persistence problem that makes curing difficult.
Solution Approach 2:
The patent employs preliminary anti-action by using NTCP inhibitors to block viral entry before infection can establish. This preemptive blockade prevents the formation of the stable cccDNA template, countering the virus's ability to maintain long-term gene expression and resist eradication by conventional drugs.
Data Source
AI summary
Provided is a host factor specific for hepatitis B virus (HBV) infection. The specific host factor CREBH can remarkably enhance HBV infection. The specific host factor can, on the one hand, enhance entry of HBV, and on the other hand, enhance transcription of HBV to some extent. In the CREBH regulatory pathway there is a specific host factor SCARF2. During HBV infection, an N-terminus EGF-like domain of SCARF2 plays a crucial role in the infection and entry of HBV. The two correlated specific host factors provide a new target for inhibiting HBV infection.